HomeBUSINESS
BUSINESS

Imfinzi, Gazyva Now Available in Japan
(Aug.30.2018)

AstraZeneca’s anti-PD-L1 antibody Imfinzi (durvalumab) and Chugai Pharmaceutical’s cancer treatment Gazyva (obinutuzumab) hit the Japan market on August 29 upon their NHI price listing the same day ...
(LOG IN FOR FULL STORY)